Audentes Therapeutics (NASDAQ: BOLD) reported Q2 EPS of ($1.01), $0.03 better than the analyst estimate of ($1.04)."It is a very ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE